AugenStock brinzopt (Brinzolamide Opthalmic Suspension USP 1% w/v) contains Brinzolamide is a Carbonic anhydrase (CA) is an enzyme found in many tissues of the body, including the eye. Carbonic anhydrase catalyses the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid.
Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. The result is a reduction in intraocular pressure (IOP) which is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. Brinzolamide, an inhibitor of carbonic anhydrase II (CA-II), the predominant iso-enzyme in the eye, with an in vitro IC50 of 3.2 nM and a Ki of 0.13 nM against CA-II.
Indications
AugenStock brinzopt (Brinzolamide Opthalmic Suspension USP 1% w/v) is indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma